Expertise in
3
conditions

Ming Q. Shi

651 Dongfeng East Road, 
Guangzhou, CN 
Expertise in
3
conditions
651 Dongfeng East Road, 
Guangzhou, CN 

Overview

Ming Shi practices practicing medicine in Guangzhou, China.

Shi is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Liver Cancer, Invertebral Disc Disease, Cerebral Hypoxia, Hepato-Pancreato-Biliary Surgery, and Hepatectomy.

They are actively involved in clinical research, co-authoring 191 peer reviewed articles and participating in 8 clinical trials.

Locations

651 Dongfeng East Road, Guangzhou, 510060, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase Ⅱ Study of Second-line Treatment Comparing Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, 5-fluorouracil and Leucovorin With Sorafenib in Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization
Randomized Phase Ⅱ Study of Second-line Treatment Comparing Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, 5-fluorouracil and Leucovorin With Sorafenib in Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization
Enrollment Status: Withdrawn
Publish Date: July 11, 2023
Intervention Type: Drug
Study Drugs: Hepatic Arterial Infusion Chemotherapy of FOLFOX, Sorafenib
Study Phase: Phase 2
Sorafenib Alone Versus Sorafenib Combined With Hepatic Arterial Chemoinfusion for Advanced HCC With Portal Vein Tumor Thrombosis: a Multicentre Randomised Controlled Trial
Sorafenib Alone Versus Sorafenib Combined With Hepatic Arterial Chemoinfusion for Advanced HCC With Portal Vein Tumor Thrombosis: a Multicentre Randomised Controlled Trial
Enrollment Status: Completed
Publish Date: December 05, 2019
Intervention Type: Drug, Procedure
Study Phase: Phase 3
Lenvatinib Plus Programmed Cell Death Protein-1 (PD-1) Antibody for Intermediate-stage Hepatocellular Carcinoma Beyond Up-to-seven Criteria
Lenvatinib Plus Programmed Cell Death Protein-1 (PD-1) Antibody for Intermediate-stage Hepatocellular Carcinoma Beyond Up-to-seven Criteria
Enrollment Status: Withdrawn
Publish Date: May 06, 2019
Intervention Type: Drug
Study Phase: Phase 2
Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Programmed Cell Death Protein-1 Antibody Versus Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Advanced Hepatocellular Carcinoma
Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Programmed Cell Death Protein-1 Antibody Versus Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Advanced Hepatocellular Carcinoma
Enrollment Status: Withdrawn
Publish Date: May 06, 2019
Intervention Type: Drug, Procedure
Study Phase: Phase 2
Transarterial Chemoembolization Plus Programmed Cell Death Protein-1 Antibody Versus Transarterial Chemoembolization Alone for Unresectable Hepatocellular Carcinoma
Transarterial Chemoembolization Plus Programmed Cell Death Protein-1 Antibody Versus Transarterial Chemoembolization Alone for Unresectable Hepatocellular Carcinoma
Enrollment Status: Withdrawn
Publish Date: May 02, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma
Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: March 06, 2019
Intervention Type: Other
Study Phase: Phase 3
Chemoembolization of Unresectable Hepatocellular Carcinoma With or Without Mixing the Chemotherapy With Lipiodol: Effectiveness and Safety. A Prospective and Randomized Clinical Trial.
Chemoembolization of Unresectable Hepatocellular Carcinoma With or Without Mixing the Chemotherapy With Lipiodol: Effectiveness and Safety. A Prospective and Randomized Clinical Trial.
Enrollment Status: Completed
Publish Date: March 06, 2019
Intervention Type: Other
Study Phase: Phase 3
The Efficacy and Safety of Retreatment With Transcatheter Arterial Infusion (TAI) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
The Efficacy and Safety of Retreatment With Transcatheter Arterial Infusion (TAI) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: January 11, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

191 Total Publications

Application of aptamer nucleic acid test strips in the detection of tumor markers for colorectal cancer.
Application of aptamer nucleic acid test strips in the detection of tumor markers for colorectal cancer.
Journal: The Analyst
Published: August 30, 2026

Frequently Asked Questions about Ming Q. Shi

Is Ming Q. Shi a top-rated expert for Liver Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Ming Q. Shi is classified as an Distinguished expert for Liver Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ming Q. Shi participate in research or clinical trials?

Yes. Ming Q. Shi has published 191 articles and abstracts on conditions like Liver Cancer. You can view a list of Ming Q. Shi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shi's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile